Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation

CONTEXT: Pasireotide-LAR, a second-generation somatostatin receptor ligand (SRL), is recommended for patients with acromegaly as second-line treatment. Its efficacy and safety were assessed in clinical trials; however, the real-world evidence is still scarce. OBJECTIVE: The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Stelmachowska-Banaś, Maria, Czajka-Oraniec, Izabella, Tomasik, Agnieszka, Zgliczyński, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821488/
https://www.ncbi.nlm.nih.gov/pubmed/34498217
http://dx.doi.org/10.1007/s11102-021-01185-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821488/
https://www.ncbi.nlm.nih.gov/pubmed/34498217
http://dx.doi.org/10.1007/s11102-021-01185-w

Ejemplares similares